Teprotumumab treatment of moderate-to-severe thyroid-associated ophthalmopathy refractory to systemic steroids and orbital radiation: A case report and literature review
10.3760/cma.j.cn311282-20240715-00315
- VernacularTitle:替妥木单抗成功治疗一例糖皮质激素冲击及眼眶放射治疗失败的中重度甲状腺相关眼病的病例报道及文献复习
- Author:
Cunxia FAN
1
;
Jingwen YU
1
;
Tuanyu FANG
1
Author Information
1. 海南省人民医院，海南医科大学附属海南医院内分泌科，海口 570311
- Publication Type:Journal Article
- Keywords:
Thyroid-associated ophthalmopathy;
Teprotumumab;
Proptosis;
Diplopia
- From:
Chinese Journal of Endocrinology and Metabolism
2025;41(4):328-332
- CountryChina
- Language:Chinese
-
Abstract:
This case report highlights the successful treatment of moderate-to-severe thyroid-associated ophthalmopathy(TAO) with teprotumumab in a patient who had previously failed multiple therapies, including intravenous steroid pulse therapy, local thyroid injections of cyclophosphamide, octreotide and dexamethasone, tocilizumab treatment, total thyroidectomy, and orbital radiation. Despite these interventions, there was no improvement in TAO. Following treatment with teprotumumab, the patient experienced a reduction of 5 mm in left eye proptosis and 4 mm in right eye proptosis, a 6-point decrease in the clinical activity score(CAS), a 2-point reduction in the diplopia score, and a significant improvement in quality of life, with sustained effects lasting 72 weeks. The treatment was well tolerated, with mild side effects including muscle spasm, fatigue, and dryness of the skin and nasal mucosa. This case report aims to raise clinical awareness regarding efficacy and safety of teprotumumab.
